Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions

Objectives: Onabotulinum toxin A (ONA, Botox (R)) and abobotulinum toxin A (ABO, Dysport (R)) are most frequently used in the treatment of movement disorders. The aim of this study was to identify the dose conversion ratio (ABO dose:ONA dose), comparative efficacy, and adverse events in patients who switched from ONA to ABO

Restless legs syndrome in migraine patients at an outpatient clinic

© Copyright 2022 by the University of Health Sciences Turkey,Gülhane Faculty of Medicine / Gülhane Medical Journal published by Galenos Publishing House.Aims: The prevalence of Restless legs syndrome (RLS) in migraine patients is estimated to be 8.7-39.0%. In this study,we set out to compare the frequency of RLS in patients diagnosed with migraine with headache free participants. Methods: We included 201 patients with migraine with or without aura and age and gendermatched 102 headache free group from outpatient setting in this cross-sectional study. None of the migraine patients were receiving prophylactic medications that could affect dopamine metabolism. Patients with comorbidities such as kidney disease,Parkinson’s disease,rheumatoid arthritis,and polyneuropathy were excluded from this study. The headache free participants had no neurological or systemic disease,no addiction/and no medical treatment. The frequency and severity (with RLS Rating Scale) of RLS was examined in two groups. Results: 40.3% (n=81) of the migraine patients met the diagnostic criteria for RLS than the headaches-free participants (15.7%,n=16) (p<0.001). The RLS (+) and RLS (-) migraine groups were similar in terms of age,gender,number of attacks per month,presence of aura,smoking,and family history for RLS. Disease duration was longer in the migraine patients with RLS and RLS severity was higher in patients with longer disease duration (p<0.001 and p=0.05). Five of six patients with hypertension and migraine patients had RLS (vs. 76 of 195 for patients without hypertension,p=0.04). Logistic regression analysis showed a significant association only between the disease duration and the presence of RLS [Odds ratio: 13.25,(95% confidence interval: 5.62-31.24),p=0.001]. Conclusions: This study found almost three times higher frequency of RLS in patients with migraine. RLS symptoms should be questioned during the management of patients with a migraine diagnosis,particularly in long-standing disease

Patient preference of device-based treatment of Parkinson's disease

Introductio

Apomorphine in the Treatment of Parkinson's Disease

Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson's disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a "treatment management guideline," which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature

Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience

Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson's disease (PD)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience

Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson's disease (PD)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience

Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson's disease (PD). Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44 patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity of the survey were evaluated with intraclass correlation coefficients for every question separately. Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63 months. Percentages of the patients who reported they were `better' after LCIG treatment were as follows: 80\% for time spent off, 55\% for dyskinesia, 65\% for tremor, 85\% for gait disorder, 50\% for pain, 50\% for sleep disorders, 42.5\% for depression, 32.5\% for incontinence, and 70\% for activities of daily living. Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items. Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease